RBC reiterates Santarus at outperform, ups target

RBC Capital Markets analyst Douglas Miehm reiterated Santarus Inc. at outperform, speculative risk, and raised its price target to $10, from $8. The company announced a licensing deal with Schering-Plough for Zegerid OTC worth $15 million upfront. Santarus may also receive an additional $65 million in milestone payments. Shares of the San Diego-based pharmaceutical company were up 3 cents, or 0.34%, at $8.97. (Nasdaq: SNTS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.